Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001245726 | SCV001419029 | benign | Nemaline myopathy 2 | 2023-11-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003263894 | SCV003954667 | uncertain significance | Inborn genetic diseases | 2023-05-23 | criteria provided, single submitter | clinical testing | The c.6388G>A (p.A2130T) alteration is located in exon 49 (coding exon 47) of the NEB gene. This alteration results from a G to A substitution at nucleotide position 6388, causing the alanine (A) at amino acid position 2130 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Ce |
RCV003311967 | SCV004011204 | uncertain significance | not provided | 2023-04-01 | criteria provided, single submitter | clinical testing | NEB: PM2, BP4 |
Natera, |
RCV001245726 | SCV002079679 | uncertain significance | Nemaline myopathy 2 | 2020-01-24 | no assertion criteria provided | clinical testing |